Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) shares saw an uptick in trading volume on Monday. Approximately 26,442 shares changed hands during mid-day trading, an increase of 373% from the average daily volume of 5,590 shares. The stock last traded at $7.27 and had previously closed at $7.25.
Wall Street Analysts Forecast Growth
Separately, Zacks Research upgraded shares of Oxford BioMedica to a “hold” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Hold rating. According to MarketBeat.com, the company currently has an average rating of “Hold”.
View Our Latest Stock Report on OXBDF
Oxford BioMedica Stock Performance
The firm’s 50-day simple moving average is $6.83 and its 200 day simple moving average is $8.24.
Oxford BioMedica Company Profile
Oxford BioMedica is a United Kingdom-based contract development and manufacturing organization (CDMO) focused on cell and gene therapies. The company supports biopharmaceutical developers with the design, development, testing and manufacture of viral vectors and other biological materials used in advanced therapies.
Its services include process and analytical development, clinical and commercial-scale manufacturing, quality testing, regulatory support and supply-chain services. Oxford BioMedica has particular expertise in lentiviral vectors, which are used to deliver genetic material into cells, and also provides capabilities involving adeno-associated virus and other vector technologies.
Founded in 1995 and headquartered in Oxford, England, the company serves biotechnology and pharmaceutical customers internationally.
Further Reading
- Five stocks we like better than Oxford BioMedica
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
